NZ599558A - Dosing regimen associated with long-acting injectable paliperidone esters - Google Patents

Dosing regimen associated with long-acting injectable paliperidone esters

Info

Publication number
NZ599558A
NZ599558A NZ599558A NZ59955810A NZ599558A NZ 599558 A NZ599558 A NZ 599558A NZ 599558 A NZ599558 A NZ 599558A NZ 59955810 A NZ59955810 A NZ 59955810A NZ 599558 A NZ599558 A NZ 599558A
Authority
NZ
New Zealand
Prior art keywords
injectable
patient
paliperidone palmitate
day
injectable paliperidone
Prior art date
Application number
NZ599558A
Other languages
English (en)
Inventor
Cristiana Gassmann-Mayer
David W Hough
Bart M M Remmerie
Peter H Lewyn-Briscoe
Srihari Gopal
Mahesh N Samtani
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43302985&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ599558(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of NZ599558A publication Critical patent/NZ599558A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NZ599558A 2009-10-30 2010-10-29 Dosing regimen associated with long-acting injectable paliperidone esters NZ599558A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25669609P 2009-10-30 2009-10-30
PCT/US2010/054807 WO2011053829A1 (en) 2009-10-30 2010-10-29 Dosing regimen associated with long-acting injectable paliperidone esters

Publications (1)

Publication Number Publication Date
NZ599558A true NZ599558A (en) 2014-09-26

Family

ID=43302985

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ599558A NZ599558A (en) 2009-10-30 2010-10-29 Dosing regimen associated with long-acting injectable paliperidone esters

Country Status (12)

Country Link
US (2) US20110105536A1 (enExample)
EP (1) EP2493473A1 (enExample)
JP (2) JP2013509435A (enExample)
KR (1) KR20120116401A (enExample)
CN (1) CN102802631A (enExample)
AU (2) AU2010313290A1 (enExample)
BR (1) BR112012010195A2 (enExample)
CA (1) CA2742393A1 (enExample)
CL (1) CL2012001110A1 (enExample)
MX (1) MX2012005083A (enExample)
NZ (1) NZ599558A (enExample)
WO (1) WO2011053829A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA72189C2 (uk) 1997-11-17 2005-02-15 Янссен Фармацевтика Н.В. Фармацевтична композиція, що містить водну суспензію субмікронних ефірів 9-гідроксирисперидон жирних кислот
SI2234617T2 (sl) 2007-12-19 2025-05-30 Janssen Pharmaceutica Nv Režim odmerjanja v zvezi z dolgodelujočimi paliperidonijevimi estri za injiciranje
US9271939B2 (en) 2010-03-15 2016-03-01 Inventia Healthcare Private Limited Stabilized prolonged release pharmaceutical composition comprising atypical antipsychotic
FI3156056T3 (fi) 2011-03-18 2024-03-01 Alkermes Pharma Ireland Ltd Sorbitaaniestereitä käsittäviä farmaseuttisia koostumuksia
CN102993200B (zh) * 2011-09-10 2016-02-03 鲁翠涛 帕潘立酮氨基酸酯及其制备方法
ES2950418T3 (es) 2012-03-19 2023-10-09 Alkermes Pharma Ireland Ltd Composiciones farmacéuticas que comprenden alcohol bencílico
US10004807B2 (en) 2012-03-19 2018-06-26 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising fatty acid esters
WO2013142202A1 (en) 2012-03-19 2013-09-26 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising glycerol esters
CA2885196C (en) 2012-09-19 2021-06-22 Alkermes Pharma Ireland Limited Pharmaceutical compositions having improved storage stability
CN106132415A (zh) 2014-03-20 2016-11-16 奥克梅斯制药爱尔兰有限公司 具有增加的注射速度的阿立哌唑制剂
ES2802299T3 (es) * 2015-04-07 2021-01-18 Janssen Pharmaceuticals Inc Régimen de dosificación para dosis olvidadas para ésteres de paliperidona inyectables de acción prolongada
ITUB20155193A1 (it) * 2015-11-03 2017-05-03 Italfarmaco Spa Sospensioni orali di Givinostat fisicamente e chimicamente stabili
US11273158B2 (en) 2018-03-05 2022-03-15 Alkermes Pharma Ireland Limited Aripiprazole dosing strategy
US12431230B2 (en) 2019-09-25 2025-09-30 Janssen Pharmaceuticals, Inc. Interconnection of drug administration systems
EP4208217A1 (en) * 2020-09-02 2023-07-12 Janssen Pharmaceutica NV Pre-filled syringe with optimized stopper placement
DK4025188T3 (da) 2020-11-30 2024-03-04 Janssen Pharmaceutica Nv Doseringsregimer associeret med injicerbare paliperidonformuleringer med forlænget frigivelse
EP4025189B1 (en) 2020-11-30 2024-06-05 Janssen Pharmaceutica NV Dosing regimens associated with extended release paliperidone injectable formulations
EP4385564A3 (en) 2020-11-30 2024-10-09 JANSSEN Pharmaceutica NV Dosing regimens associated with extended release paliperidone injectable formulations
EP4308077A1 (en) * 2021-03-17 2024-01-24 MedinCell S.A. Long acting injectable formulation comprising risperidone and biodegradable polymers
CA3229731A1 (en) 2021-08-20 2023-02-23 Janssen Pharmaceutica Nv Dosing regimens associated with extended release paliperidone injectable formulations

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5254556A (en) 1988-11-07 1993-10-19 Janssen Pharmaceutica N.V. 3-piperidinyl-1,2-benzisoxazoles
TW487572B (en) 1996-05-20 2002-05-21 Janssen Pharmaceutica Nv Aqueous suspensions of 9-hydroxyrisperidone fatty acid esters
UA72189C2 (uk) 1997-11-17 2005-02-15 Янссен Фармацевтика Н.В. Фармацевтична композиція, що містить водну суспензію субмікронних ефірів 9-гідроксирисперидон жирних кислот
KR100338776B1 (ko) 2000-07-11 2002-05-31 윤종용 멀티 로우 어드레스 테스트 가능한 반도체 메모리 장치 및그 테스트 방법
EP1879890A1 (en) 2005-04-25 2008-01-23 Janssen Pharmaceutica N.V. Preparation of aseptic 3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-9-hydroxy-2-methyl-4h-pyridio[1,2-a]pyrimidin-4-one palmitate ester
US20070197591A1 (en) * 2005-12-12 2007-08-23 Sandra Boom Use of paliperidone for the treatment of a mental disorder in a psychiatric patient with reduced hepatic function
TW200825077A (en) * 2006-08-14 2008-06-16 Teva Pharma Crystal forms of 9-hydroxy-risperidone (paliperidone)
SI2234617T2 (sl) 2007-12-19 2025-05-30 Janssen Pharmaceutica Nv Režim odmerjanja v zvezi z dolgodelujočimi paliperidonijevimi estri za injiciranje

Also Published As

Publication number Publication date
AU2015243103A1 (en) 2015-11-05
EP2493473A1 (en) 2012-09-05
CA2742393A1 (en) 2011-05-05
JP2013509435A (ja) 2013-03-14
CN102802631A (zh) 2012-11-28
BR112012010195A2 (pt) 2016-04-26
CL2012001110A1 (es) 2012-10-19
MX2012005083A (es) 2012-09-28
WO2011053829A1 (en) 2011-05-05
AU2010313290A1 (en) 2012-05-17
US20110105536A1 (en) 2011-05-05
US20130331402A1 (en) 2013-12-12
JP2016102123A (ja) 2016-06-02
KR20120116401A (ko) 2012-10-22

Similar Documents

Publication Publication Date Title
NZ599558A (en) Dosing regimen associated with long-acting injectable paliperidone esters
NZ586221A (en) Dosing regimen associated with long acting injectable paliperidone esters
JP2013509435A5 (enExample)
UA115139C2 (uk) Спосіб доставки фармацевтичної композиції, яка містить омепразол й ацетилсаліцилову кислоту, пацієнту
NZ732507A (en) Improved compositions for treating muscular dystrophy
NZ703153A (en) Factor viii-fc chimeric and hybrid polypeptides, and methods of use thereof
JP2012193216A5 (enExample)
MX2022008236A (es) Metodos para administrar altas concentraciones de oxido nitrico.
MY159353A (en) Pirfenidone treatment for patients with atypical liver function
RU2015127794A (ru) Введение антисмысловых олигонуклеотидов, комплементарных человеческому аполипопротеину в
RU2613324C3 (ru) Композиция для контролируемой стимуляции яичников
WO2013078440A3 (en) Enhanced treatment regimens using mtor inhibitors
GR1007832B (el) Αδρανοποιητες της ακτιβινης και χρηση τους για την θεραπεια ασθενειων που σχετιζονται με παρεκκλινουσα ενεργοποιηση της "αμυντικης αποκρισης του ξενιστη"
EP4349323A3 (en) Dosing regimen for missed doses for long-acting injectable paliperidone esters
UA105191C2 (ru) Лечение пирфенидоном пациентов с атипической функцией печени
JP2018510894A5 (enExample)
NZ598465A (en) Dosage regimens for hcv combination therapy comprising bi201335, interferon alpha and ribavirin
EP3970729A3 (en) Methods of administering high concentrations of nitric oxide
MX2013003523A (es) Composicion farmaceutica de dosis baja.
RU2015127834A (ru) Способы лечения диабета путем введения антагониста рецептора глюкагона в сочетании с ингибитором поглощения холестерина
MX2015009546A (es) Dosificacion aumentada de efavirenz para el tratamiento de cancer.
JP2014530246A5 (enExample)
JOP20170044B1 (ar) تركيبة صيدلانية تشتمل على hgh ناتج عن عودة الارتباط الجيني لعلاج نقص هرمون النمو
SI2686002T1 (en) A method for reducing influenza-like symptoms associated with intramuscular delivery of interferon by the rapid titration-enhancing regimen
NZ590489A (en) Unit dosage of apadenoson

Legal Events

Date Code Title Description
AABA Application abandoned
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 29 OCT 2017 BY AJ PARK

Effective date: 20150505

LAPS Patent lapsed